Application
Fig1: Western blot analysis of CLGN on human CLGN recombinant protein using anti-CLGN antibody at 1/1,000 dilution.
Application
Fig2: Western blot analysis of CLGN on HEK293 (1) and CLGN-hIgGFc transfected HEK293 (2) cell lysate using anti-CLGN antibody at 1/1,000 dilution.
Application
Fig3: Western blot analysis of CLGN on different cell lysate using anti-CLGN antibody at 1/1,000 dilution.Positive control:Line1:LNCaPLine2:HepG2Line3:PC-3Line4:Raji
Application
Fig4: ICC staining CLGN (green) in HepG2 cells. The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Application
Fig5: Immunohistochemical analysis of paraffin-embedded human breast cancer tissue using anti-CLGN antibody. Counter stained with hematoxylin.
Application
Fig6: Immunohistochemical analysis of paraffin-embedded human esophageal cancer tissue using anti-CLGN antibody. Counter stained with hematoxylin.
Application
Fig7: Flow cytometric analysis of HEK293 cells with CLGN antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; purple).